ArticleClinical and experimental medicine2025
The necessity of adjuvant chemotherapy in young patients with T
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy clearly adversely affects fertility in women of childbearing age. But it is not yet clear whether chemotherapy at the expense of fertility can benefit younger patients with early-stage breast cancer. We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database and the Shanghai Jiao Tong University Breast Cancer Data Base spanning from 2010 to 2020 to investigate early-stage breast malignant carcinoma in patients aged between 20 and 39 years. To address covariate imbalance, propensity score matching (PSM) was employed with a ratio of 1:1 and caliper set at 0.02 standard deviation of propensity score. Univariate and multivariate analyses were performed to evaluate the impact of chemotherapy on both breast cancer-specific survival (BCSS) and overall survival (OS). We identified a total of 6265 patients with complete information about breast cancer. Among them, 3855 patients received chemotherapy. Following successful PSM, we obtained a matched cohort comprising 3038 patients where the characteristics between the two groups were balanced except for race. Kaplan-Meier survival analysis revealed no significant differences in BCSS (P = 0.183) and OS (P = 0.295) between the chemotherapy group and no-chemotherapy group. Similarly, in matched dataset. multivariate COX analysis revealed that chemotherapy did not significantly reduce the risk of BCSS (HR 1.332; 95% CI [0.865-2.051], P = 0.193) and OS (HR 1.225; 95% CI [0.818-1.833], P = 0.324). The chemotherapy group did not demonstrate a superior benefit in any of the subgroups when stratified analyses were conducted based on molecular subtype, tumor size, age, and ethnicity. Chemotherapy fails to significantly improve prognostic outcomes in young patients diagnosed with early-stage breast cancer. With the help of genetic testing, these patients can expect further step-down therapy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.